Figure 4.
PFS after end-of-treatment analysis. Kaplan-Meier estimates of PFS in all participants after the end of treatment (A) and according to CXCR4 mutational status (B), time on treatment (C), and VGPR attainment (D).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.